|
GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
|
EP2569434B1
(en)
|
2010-05-14 |
2019-09-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating leukemia and related disorders
|
|
CN104311562B
(zh)
|
2010-05-14 |
2017-07-04 |
达那-法伯癌症研究所 |
用于治疗瘤形成、炎性疾病和其他失调的组合物和方法
|
|
JP6022442B2
(ja)
|
2010-05-14 |
2016-11-09 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
男性用避妊組成物および使用方法
|
|
US9249161B2
(en)
|
2010-12-02 |
2016-02-02 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
US9422292B2
(en)
|
2011-05-04 |
2016-08-23 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201107325D0
(en)
*
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2012174487A2
(en)
|
2011-06-17 |
2012-12-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
WO2013097052A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
|
WO2013155695A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbott Laboratories |
Isoindolone derivatives
|
|
US9624244B2
(en)
|
2012-06-06 |
2017-04-18 |
Constellation Pharmaceuticals, Inc. |
Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
CN104718201A
(zh)
|
2012-06-12 |
2015-06-17 |
艾伯维公司 |
吡啶酮和哒嗪酮衍生物
|
|
EP2861255B1
(en)
|
2012-06-19 |
2019-10-09 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
|
WO2014096965A2
(en)
|
2012-12-21 |
2014-06-26 |
Rvx Therapeutics Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
AU2014249192B2
(en)
|
2013-03-11 |
2017-12-21 |
The Regents Of The University Of Michigan |
BET bromodomain inhibitors and therapeutic methods using the same
|
|
ES2915658T3
(es)
*
|
2013-03-14 |
2022-06-24 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolin-2,3-disustituida y su uso como inhibidores de bromodominio
|
|
ES2654362T3
(es)
|
2013-03-14 |
2018-02-13 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Furopiridinas como inhibidores de bromodominio
|
|
US9695179B2
(en)
*
|
2013-03-14 |
2017-07-04 |
Convergene Llc |
Methods and compositions for inhibition of bromodomain-containing proteins
|
|
US9714946B2
(en)
|
2013-03-14 |
2017-07-25 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
KR102216288B1
(ko)
|
2013-03-15 |
2021-02-18 |
인사이트 홀딩스 코포레이션 |
Bet 단백질 저해제로서의 삼환식 복소환
|
|
SG11201506829XA
(en)
|
2013-04-26 |
2015-12-30 |
Beigene Ltd |
Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
|
|
EP3010918B1
(en)
|
2013-06-21 |
2018-08-15 |
Zenith Epigenetics Ltd. |
Novel substituted bicyclic compounds as bromodomain inhibitors
|
|
PT3010503T
(pt)
|
2013-06-21 |
2020-06-16 |
Zenith Epigenetics Corp |
Novos inibidores bicíclicos de bromodomínios
|
|
AR096758A1
(es)
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
|
HK1223364A1
(zh)
*
|
2013-06-28 |
2017-07-28 |
Abbvie Inc. |
布罗莫结构域抑制剂
|
|
ES2635560T3
(es)
|
2013-07-08 |
2017-10-04 |
Incyte Holdings Corporation |
Heterociclos tricíclicos como inhibidores de la proteína NET
|
|
JP2016531113A
(ja)
|
2013-07-25 |
2016-10-06 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
転写因子の阻害剤およびその使用
|
|
KR20160038008A
(ko)
|
2013-07-31 |
2016-04-06 |
제니쓰 에피제네틱스 코포레이션 |
브로모도메인 억제제로서 신규 퀴나졸리논
|
|
CA3148196A1
(en)
*
|
2013-10-18 |
2015-04-23 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitors
|
|
MX379463B
(es)
|
2013-11-08 |
2025-03-10 |
Dana Farber Cancer Inst Inc |
Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
|
|
HUE053645T2
(hu)
|
2013-11-18 |
2021-07-28 |
Forma Therapeutics Inc |
Tetrahidrokinolin kompozíciók mint BET bromodomén inhibitorok
|
|
RU2720237C2
(ru)
|
2013-11-18 |
2020-04-28 |
Форма Терапеутикс, Инк. |
Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
|
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
CA2934788C
(en)
*
|
2014-01-09 |
2021-12-07 |
Orion Corporation |
Bicyclic heterocyclic derivatives as bromodomain inhibitors
|
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
|
EP3099693A4
(en)
|
2014-01-31 |
2017-08-16 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
CA2936865A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diaminopyrimidine benzenesulfone derivatives and uses thereof
|
|
MX2016009976A
(es)
|
2014-01-31 |
2016-11-15 |
Dana Farber Cancer Inst Inc |
Derivados de diazepam y sus usos.
|
|
CN107074861A
(zh)
|
2014-02-28 |
2017-08-18 |
密执安大学评议会 |
作为bet溴结构域抑制剂的9h嘧啶并[4，5‑b]吲哚和相关类似物
|
|
WO2015131113A1
(en)
|
2014-02-28 |
2015-09-03 |
Tensha Therapeutics, Inc. |
Treatment of conditions associated with hyperinsulinaemia
|
|
PT3134403T
(pt)
|
2014-04-23 |
2020-05-18 |
Incyte Corp |
1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7(6h)-onas como inibidores das proteínas bet
|
|
SI3157928T1
(sl)
|
2014-06-20 |
2019-06-28 |
Constellation Pharmaceuticals, Inc. |
Kristalinične oblike 2-((4S)-6-(4-klorofenil)-1-metil-4H-benzo(C)izoksazolo(4,5-E)azepin-4-il acetamida
|
|
BR112017002369A2
(pt)
|
2014-08-08 |
2017-12-05 |
Dana Farber Cancer Inst Inc |
derivados de diazepana e usos dos mesmos
|
|
CA2955077A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
HUE041694T2
(hu)
*
|
2014-09-12 |
2019-05-28 |
Glaxosmithkline Ip No 2 Ltd |
Tetrahidrokvinolin származékok mint bromodomén inhibitorok
|
|
WO2016044130A1
(en)
|
2014-09-15 |
2016-03-24 |
Incyte Corporation |
Tricyclic heterocycles for use as bet protein inhibitors
|
|
MX376748B
(es)
|
2014-10-27 |
2025-03-07 |
Tensha Therapeutics Inc |
Inhibidores del bromodominio.
|
|
WO2016087942A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Corp. |
Substituted pyridines as bromodomain inhibitors
|
|
CA2966298A1
(en)
|
2014-12-01 |
2016-06-09 |
Zenith Epigenetics Ltd. |
Substituted pyridinones as bromodomain inhibitors
|
|
CA2966449A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Ltd. |
Substituted heterocycles as bromodomain inhibitors
|
|
EP3233846A4
(en)
|
2014-12-17 |
2018-07-18 |
Zenith Epigenetics Ltd. |
Inhibitors of bromodomains
|
|
WO2016138332A1
(en)
|
2015-02-27 |
2016-09-01 |
The Regents Of The University Of Michigan |
9h-pyrimido [4,5-b] indoles as bet bromodomain inhibitors
|
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201504694D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
WO2016210275A1
(en)
|
2015-06-26 |
2016-12-29 |
Tensha Therapeutics, Inc. |
Treatment of nut midline carcinoma
|
|
EP3334725B1
(en)
|
2015-08-10 |
2025-04-23 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain and extra terminal (bet) inhibitor and a protein phosphatase 2a (pp2a) activator for treating bet inhibitor resistant cancer
|
|
WO2017037116A1
(en)
|
2015-09-02 |
2017-03-09 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
|
BR112018004617A2
(pt)
|
2015-09-11 |
2018-09-25 |
Dana Farber Cancer Inst Inc |
acetamida tienotriazoldiazepinas e usos das mesmas
|
|
JP2018526421A
(ja)
|
2015-09-11 |
2018-09-13 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
シアノチエノトリアゾロジアゼピンおよびこれらの使用
|
|
US10370356B2
(en)
|
2015-09-22 |
2019-08-06 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
|
EP3359531B1
(en)
|
2015-10-05 |
2020-08-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
2-oxo-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors
|
|
WO2017075377A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
CN108472295B
(zh)
|
2015-11-25 |
2022-04-15 |
达纳-法伯癌症研究所股份有限公司 |
二价溴结构域抑制剂及其用途
|
|
ES2882066T3
(es)
|
2016-02-15 |
2021-12-01 |
Univ Michigan Regents |
1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET
|
|
EP3440066B1
(en)
|
2016-04-06 |
2022-11-30 |
The Regents of The University of Michigan |
Mdm2 protein degraders
|
|
EP3440082A1
(en)
|
2016-04-06 |
2019-02-13 |
The Regents of The University of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
CA3018358A1
(en)
|
2016-04-07 |
2017-10-12 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Pyridyl derivatives as bromodomain inhibitors
|
|
EP3440075B1
(en)
|
2016-04-07 |
2020-01-29 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Benzo[b]furans as bromodomain inhibitors
|
|
SG11201808729WA
(en)
|
2016-04-12 |
2018-11-29 |
Univ Michigan Regents |
Bet protein degraders
|
|
PT3442972T
(pt)
|
2016-04-15 |
2020-05-29 |
Abbvie Inc |
Inibidores de bromodomínio
|
|
JP7160688B2
(ja)
*
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
EP3464242A1
(en)
|
2016-05-24 |
2019-04-10 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridine dicarboxamide derivatives as bromodomain inhibitors
|
|
CN109715625B
(zh)
|
2016-06-20 |
2022-04-19 |
因赛特公司 |
Bet抑制剂的结晶固体形式
|
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
EP3512853B1
(en)
|
2016-09-13 |
2020-12-23 |
The Regents of The University of Michigan |
Fused 1,4-diazepines as bet protein degraders
|
|
CA3036834A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as bet protein degraders
|
|
AU2017345468B2
(en)
*
|
2016-10-20 |
2022-06-02 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
|
WO2018111805A1
(en)
|
2016-12-13 |
2018-06-21 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
|
US11046709B2
(en)
|
2017-02-03 |
2021-06-29 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as BET bromodomain inhibitors
|
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
JOP20190192A1
(ar)
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
WO2019055444A1
(en)
|
2017-09-13 |
2019-03-21 |
The Regents Of The University Of Michigan |
DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
|
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
治療前列腺癌之組合療法
|
|
TWI882964B
(zh)
|
2018-09-13 |
2025-05-11 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
WO2023041744A1
(en)
|
2021-09-17 |
2023-03-23 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
JP2025514712A
(ja)
|
2022-04-19 |
2025-05-09 |
ヌエヴォリューション・アクティーゼルスカブ |
ブロモドメインに対して活性な化合物
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|